Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Toxicol Appl Pharmacol ; 459: 116361, 2023 01 15.
Article in English | MEDLINE | ID: mdl-36584762

ABSTRACT

Osteoarthritis (OA) is a chronic debilitating degenerative disorder leading to structural, and functional anomaly of the joint. The present study tests the hypothesis that overexpression of the basic fibroblast growth factor (FGF-2) via direct rAAV-mediated gene transfer suppresses monosodium iodoacetate (MIA)-induced knee OA in rats relative to control (reporter rAAV-lacZ vector) gene transfer by intra-articular injection. Rats were treated with 20 µl rAAV-hFGF-2 on weekly basis; on days 7, 14, and 21 after single intra-articular injection of MIA (3 mg/50 µl saline). FGF-2 reduced knee joint swelling and improved motor performance and muscle coordination as evidenced by increased distance travelled, mean speed, rearing frequency in open field test (OFT) as well as fall-off latency in rotarod test together with reduced immobility time in OFT. Moreover, FGF-2 attenuated MIA-related radiological and histological alterations. Indeed, FGF-2 decreased knee joint inflammatory biomarker as demonstrated by reduced mRNA expression of toll like receptor (TLR)-4 and its downstream mediators such as tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1ß) and high motility group box (HMGB) 1. In parallel, FGF-2 attenuated knee joint degradation biomarkers as reflected by the downregulation of ADAMTS-5 mRNA expression and matrix metalloproteinase 13 (MMP-13) content together with the up-regulation of tissue inhibitor of metalloproteinase (TIMP)-1 mRNA expression. These findings suggest a potential therapeutic role for FGF-2 against MIA-induced knee OA in rats via inhibition of TLR4 signaling and activating TIMP-1, resulting in down-regulation of ADAMTS-5 and MMP-13.


Subject(s)
Cartilage, Articular , Osteoarthritis , Animals , Rats , Cartilage, Articular/metabolism , Disease Models, Animal , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/metabolism , Injections, Intra-Articular , Iodoacetic Acid , Matrix Metalloproteinase 13/genetics , Matrix Metalloproteinase 13/metabolism , Osteoarthritis/pathology , RNA, Messenger/metabolism , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-1/therapeutic use , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Humans , Recombinant Proteins/pharmacology
2.
Article in English | MEDLINE | ID: mdl-35176416

ABSTRACT

Prenatal alcohol exposure (PAE) increases alcohol consumption and risk for alcohol use disorder. This phenomenon in rodents is suggested to involve a stimulatory effect of PAE, in female more than male offspring, on neurogenesis and density of neurons expressing neuropeptides in lateral hypothalamus (LH), including melanin-concentrating hormone (MCH), known to promote alcohol intake. With evidence suggesting a role for fibroblast growth factor 2 (FGF2) and its receptor FGFR1 in stimulating neurogenesis and alcohol drinking, we investigated here whether the FGF2-FGFR1 system is involved in the PAE-induced increase in MCH neurons, in postnatal offspring of pregnant rats given ethanol orally (embryonic day 10-15) at a low-moderate (2 g/kg/day) or high (5 g/kg/day) dose. Our results demonstrate that PAE at the low-moderate but not high dose stimulates FGF2 and FGFR1 gene expression and increases the density of MCH neurons co-expressing FGF2, only in females, but FGFR1 in both sexes. PAE induces this effect in the dorsal but not ventral area of the LH. Further analysis of FGF2 and FGFR1 transcripts within individual MCH neurons reveals an intracellular, sex-dependent effect, with PAE increasing FGF2 transcripts positively related to FGFR1 in the nucleus as well as cytoplasm of females but transcripts only in the cytoplasm of males. Peripheral injection of FGF2 itself (80 µg/kg, s.c.) in pregnant rats mimics these effects of PAE. Together, these results support the involvement of the FGF2-FGFR1 system in mediating the PAE-induced, sex dependent increase in density of MCH neurons, possibly contributing to increased alcohol consumption in the offspring.


Subject(s)
Fibroblast Growth Factor 2 , Prenatal Exposure Delayed Effects , Animals , Ethanol , Female , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/metabolism , Male , Neurons , Peptides/pharmacology , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Rats , Rats, Sprague-Dawley
3.
Auris Nasus Larynx ; 48(6): 1054-1060, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33773851

ABSTRACT

OBJECTIVE: To evaluate the efficacy and safety of regenerative treatment for tympanic membrane perforation (TMP) using gelatin sponge, basic fibroblast growth factor (bFGF), and fibrin glue. METHODS: This was a multicenter, non-randomized, single-arm study conducted at tertiary referral centers. Twenty patients with chronic TMP (age 23-78 years, 6 males, 14 females) were registered from three institutions. All treated patients were included in the safety analysis population. The edges of the TMP were disrupted mechanically by myringotomy and several pieces of gelatin sponge immersed in bFGF were placed and fixed with fibrin glue to cover the perforation. The TMP was examined 4 ± 1 weeks later. The protocol was repeated up to four times until closure was complete. The main outcome measures were closure or a decrease in size of the TMP, hearing improvement, and air-bone gap evaluated 16 weeks after the final regenerative procedure (FRP). Adverse events (AEs) were monitored throughout the study. RESULTS: Total closure of the TMP at 16 weeks was achieved in 15 out of 20 patients (75.0%, 95% confidence interval [CI]: 50.9%-91.3%) and the mean decrease in size was 92.2% (95%CI: 82.9%-100.0%). The ratio of hearing improvement and the air-bone gap at 16 weeks after FRP were 100% (20/20; 95%CI: 83.2%-100%) and 5.3 ± 4.2 dB (p <0.0001), respectively. Thirteen out of 20 patients (65.0%) experienced at least one AE, but no serious AEs occurred. CONCLUSION: The results indicate that the current regenerative treatment for TMP using gelatin sponge, bFGF, and fibrin glue is safe and effective.


Subject(s)
Fibrin Tissue Adhesive , Fibroblast Growth Factor 2/therapeutic use , Gelatin Sponge, Absorbable/therapeutic use , Tympanic Membrane Perforation/therapy , Aged , Female , Fibroblast Growth Factor 2/adverse effects , Gelatin Sponge, Absorbable/adverse effects , Humans , Male , Middle Aged , Treatment Outcome
4.
Laryngoscope ; 131(9): 2059-2064, 2021 09.
Article in English | MEDLINE | ID: mdl-33107605

ABSTRACT

OBJECTIVES/HYPOTHESIS: Vocal fold atrophy, scar, and sulcus reduce the vibratory function of the vocal fold mucosa, which causes severe refractory dysphonia. We have reported encouraging preliminary results using an intracordal injection of basic fibroblast growth factor (bFGF) and showed improvement in phonatory parameters and voice. The present study summarizes our experience with 100 cases of stiffened vocal folds that were treated with bFGF injections. STUDY DESIGN: Retrospective chart review with Interstitial Review Board (IRB) approval. METHODS: Local injection of bFGF was performed in 100 cases of vocal fold pathology, which included 43 cases of vocal fold atrophy, 41 cases with scar, and 16 cases with sulcus. Ten micrograms of bFGF were injected into the vocal folds under topical anesthesia 4 times in each patient. Therapeutic outcomes were examined with maximum phonation time (MPT), voice handicap index-10 (VHI-10), and GRBAS scale. RESULTS: MPT, VHI-10, and GRBAS scores significantly improved in all pathology groups. An improvement on the VHI-10 greater than five points was observed in 82% of atrophy cases, 78% of scar cases, and 67% of sulcus cases. Improvement on the VHI-10 was significantly better in the atrophy group than the scar or sulcus groups. The mild/moderate cases of scar and sulcus showed better improvement than severe cases. CONCLUSIONS: The current large case series indicates positive effects of intracordal injection of bFGF for improvement of voice with no severe adverse events. The effects appeared best for cases of atrophy, while the treatment of severe scar and sulcus requires further improvement. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:2059-2064, 2021.


Subject(s)
Dysphonia/drug therapy , Fibroblast Growth Factor 2/administration & dosage , Hoarseness/drug therapy , Regeneration/drug effects , Vocal Cords/drug effects , Aged , Aged, 80 and over , Atrophy/diagnosis , Atrophy/pathology , Case-Control Studies , Cicatrix/diagnosis , Cicatrix/pathology , Dysphonia/etiology , Female , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/therapeutic use , Hoarseness/etiology , Humans , Injections, Intralesional/methods , Laryngeal Diseases/pathology , Male , Middle Aged , Phonation/drug effects , Retrospective Studies , Treatment Outcome , Vocal Cords/pathology , Voice/drug effects
5.
Sci China Life Sci ; 62(12): 1617-1629, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31515729

ABSTRACT

Intrauterine adhesion (IUA) is a common cause of uterine infertility and one of the most severe clinical features is endometrial fibrosis namely endometrial scarring for which there are few cures currently. Blocked angiogenesis is the main pathological change in the scarred endometrium. The fibroblast growth factor 2 (bFGF), a member of FGF family, is usually applied to promote healing of refractory ulcer and contributes to angiogenesis of tissues. In this study, the sustained-release system of bFGF 100 µg was administrated around scarred endometrium guiding by ultrasound every 4 weeks in 18 patients (2-4 times). Results showed that after treatment, the menstrual blood volume, endometrial thickness and the scarred endometrial area were improved. Histological study showed blood vessel density increased obviously. Three patients (3/18) achieved pregnancy over 20 gestational weeks. Therefore, administrating the bFGF surrounding scarred endometrium may provide a new therapeutic approach for the patients with endometrial fibrosis.


Subject(s)
Collagen/chemistry , Endometrium/drug effects , Fibroblast Growth Factor 2/pharmacology , Uterus/drug effects , Adult , Cervix Uteri/drug effects , Collagen/metabolism , Dose-Response Relationship, Drug , Endometrium/metabolism , Female , Fibroblast Growth Factor 2/administration & dosage , Fibroblast Growth Factor 2/adverse effects , Humans , Infertility, Female/drug therapy , Pilot Projects , Pregnancy , Protein Binding , Signal Transduction , Tissue Adhesions/metabolism , Treatment Outcome
6.
Acta Otorhinolaryngol Ital ; 38(3): 264-272, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29984804

ABSTRACT

SUMMARY: The objective of this study was to investigate the short- and long-term adverse effects of fibroblast growth factor-2 treatment of tympanic membrane perforations. A total of 134 patients with traumatic tympanic membrane perforations were randomly divided into two groups: an observational group and a fibroblast growth factor-2 treatment group. The closure rate, closure time and principal side-effects were compared between the groups at 6 and 12 months. At 6 months, 131 patients were examined to determine healing outcomes and short-term side-effects. The total closure rate differed significantly between the fibroblast growth factor-2 and observational groups (95.5% vs 73.4, p #x003C; 0.01). The fibroblast growth factor-treated group exhibited a significantly shorter closure time than the observational group (11.9±3.1 days vs 52.6 ± 18.1 days, p = 0.00). Three patients with secondary otitis media with effusion, and three with reperforations, were noted in the fibroblast growth factor-2 group. We additionally performed long-term follow-up on 89.1% of the patients in the observational group and 92.5% of the patients in the fibroblast growth factor-2 group; follow-up was performed 16-42 months after perforation closure. Only a small perforation of the pars flaccida developed in the fibroblast growth factor-2 group. No middle ear cholesteatoma was noted in either group. This study suggests that the topical application of fibroblast growth factor-2 to human traumatic tympanic membranes is safe. Otorrhoea was the most common short-term side-effect; other less common side-effects included otitis media with effusion and reperforation. No serious long-term side-effects were found.


Subject(s)
Fibroblast Growth Factor 2/adverse effects , Tympanic Membrane Perforation/drug therapy , Adult , Female , Humans , Male , Time Factors
7.
Cutan Ocul Toxicol ; 37(3): 258-266, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29480078

ABSTRACT

In the present investigation, the safety of novel combinational silver sulfadiazine-bFGF-loaded hydrogel was assured by performing acute skin irritation, sensitization, acute dermal toxicity, and eye irritation in compliance with the Organization for Economic Co-operation and Development guidelines. In the skin irritation study, placebo, test, and positive control (0.8% w/v aqueous solution of formaldehyde) were applied on New Zealand rabbits and monitored for abnormal skin responses including erythema and edema. The placebo and test formulation did not induce any adverse reactions and were classified as nonirritating materials. In the skin sensitization test, guinea pigs were sensitized by positive control (0.1% w/v 1-chloro-2,4-dinitrobenzene in 10% of propylene glycol as a standard skin sensitizing agent), placebo, and test formulations. Weak sensitization was observed in the placebo and test formulation treated groups. Additionally, acute dermal toxicity test was performed in Wistar rats, where no signs of toxicity were observed in biochemical, hematological, and histopathological studies. Moreover, the acute eye irritation test was carried out in rabbits and no abnormal clinical signs were evident in the cornea or iris. As a whole, these findings suggest that the hydrogel formulation does not cause any skin irritation, skin sensitizationand dermal toxic effects, and eye irritation following dermal and ocular applications, respectively. Therefore, all the findings obtained from this preclinical study indicated that this hydrogel formulation is nontoxic and safe for use in animal models.


Subject(s)
Burns/drug therapy , Fibroblast Growth Factor 2/adverse effects , Hydrogels/adverse effects , Silver Sulfadiazine/adverse effects , Skin/drug effects , Administration, Cutaneous , Administration, Ophthalmic , Animals , Anti-Infective Agents, Local , Consumer Product Safety/standards , Disease Models, Animal , Drug Evaluation, Preclinical , Eye/drug effects , Female , Guidelines as Topic , Guinea Pigs , Humans , Male , Rabbits , Rats , Rats, Wistar , Skin Tests/standards , Toxicity Tests, Acute/standards
8.
São Paulo; s.n; s.n; 2018. 165 p. ilus, tab, graf.
Thesis in Portuguese | LILACS | ID: biblio-911612

ABSTRACT

O FGF2 (Fibroblast Growth Factor 2) é um clássico fator peptídico de crescimento que ativa vias intracelulares de sinalização molecular promovendo a transição G0 → G1 e o comprometimento com o ciclo celular. Não surpreendentemente, seus papéis pró-tumoral e angiogênico estão bem caracterizados e estabelecidos na literatura. No entanto, um crescente corpo de evidências tem indicado que o FGF2 também pode exercer efeitos anti-tumorais in vitro e in vivo, em modelos murinos e também humanos. Neste contexto, nosso grupo publicou em 2008 que o FGF2 exerce um efeito antiproliferativo seletivo em células murinas malignas dependentes de alta atividade de K-Ras e H-Ras. Os genes ras compõem a família de oncogenes mais frequentemente mutada em tumores malignos humanos, alcançando aproximadamente 30% de todos os casos. O desenvolvimento de terapias contra tumores dependentes de Ras fracassou, apesar dos intensos esforços e investimentos desde a descoberta em 1982 de suas mutações ativadoras em múltiplos cânceres. O objetivo deste trabalho foi desvendar os mecanismos moleculares pelo quais o FGF2 inibe irreversivelmente a proliferação de células malignas dependentes da atividade de Ras, empregando como modelos experimentais a linhagem murina Y1 de células adrenocorticais, e 4 linhagens humanas derivadas de sarcomas de Ewing. Identificamos que o efeito citotóxico do FGF2 não se processa por um mecanismo novo e independente das viasproliferativas classicamente ativadas por fatores peptídicos de crescimento. Ao contrário, seu efeito tóxico é resultado de sinalização mitogênica exagerada decorrente de estimulação sustentada por FGF2. A ativação da via de MAPK, principal sinalização mitogênica intracelular, a níveis elevados e sustentados provoca estresse mitogênico, que se propaga para a fase S na forma de estresse replicativo. Nesta situação, a célula passa a depender exageradamente da sinalização protetora de ATR, de modo que a combinação de estimulação com FGF2 e inibição de ATR foi altamente letal para as células malignas dependentes de Ras empregadas neste trabalho. Também analisamos as bases moleculares de resistência a FGF2 exibida por células Y1 anteriormente selecionadas para resistir ao efeito tóxico do FGF2 (Y1FRs). Descobrimos que a pressão seletiva do FGF2 não teve efeito na expressão de seus receptores, mas provocou a eliminação de um dos dois cromossomos que portam a amplificação gênica de ras nesta linhagem, enquanto o segundo cromossomo foi mantido por ser a única fonte de genes ribossomais ativos. Suas cópias de ras, no entanto, mostraram-se transcricionalmente silenciadas. Além disso, as sublinhagens Y1FRs não expressam o principal RasGEF, GRP4, encontrado nas células parentais Y1, o que pode ter influenciado o surgimento do fenótipo resistente ao FGF2. As linhagens resistentes mostraram grande redução no número de cromossomos e aumento da frequência de fusões entre cromossomos não homólogos em relação às células parentais


FGF2 (Fibroblast Growth Factor 2) is a classic peptide growth factor that activates intracellular molecular signaling pathways promoting the G0 → G1 transition and cell cycle commitment. Not surprisingly, its pro-tumor and angiogenic roles are well characterized and established in the literature. However, a growing body of evidence has indicated that FGF2 may also exert anti-tumor effects in vitro and in vivo in murine and human models. In this context, our group reported in 2008 that FGF2 exerts a selective antiproliferative effect in murine cells dependent on high activity of K-Ras and H-Ras. Ras genes make up the most frequently mutated oncogene family in human malignant tumors, reaching approximately 30% of all cases. The development of therapies against Ras-dependent tumors has failed despite intense efforts and investments since the discovery in 1982 of its activating mutations in multiple cancers. The objective of this work was to uncover the molecular mechanisms by which FGF2 irreversibly inhibits the proliferation of malignant cells dependent on Ras activity, using as experimental models the Y1 murine lineage of adrenocortical malignant cells and 4 human lineages derived from Ewing sarcomas. We showed that the cytotoxic effect of FGF2 did not involve novel cell cycle regulatory pathways; instead, this cytotoxic effect is a result of sustainedhyper mitogenic stimulation by FGF2. Activation of the KRas/MAPK pathway, the major intracellular mitogenic signaling, at high and sustained levels provokes mitogenic stress, which is propagated to S phase as replicative stress. In this situation, the cell dependence on the ATR protective signaling is enhanced, so that the combination of stimulation with FGF2 and inhibition of ATR was highly lethal for the Ras dependent malignant cells employed in this work. We also analyzed the molecular basis of FGF2 resistance exhibited by Y1 cells previously selected for resistance to FGF2. We found that the selective pressure of FGF2 had no effect on the expression of its receptors but promoted the elimination of one of the two marker chromosomes that carry the K-ras amplified copies, while the second chromosome was maintained because it is the only source of active ribosomal genes; however, its K-ras amplified copies were transcriptionally silenced. In addition, the Y1FRs sublines did not express the main RasGEF, GRP4, found in the parental Y1 cells, which might have played a role in the emergence of the FGF2-resistant phenotype. The resistant Y1FRs sublines showed a large reduction in chromosome numbers and increased frequency of fusions between non-homologous chromosomes in relation to parental cells


Subject(s)
Fibroblast Growth Factor 2/analysis , Fibroblast Growth Factor 2/adverse effects , Genes, ras/genetics , Adrenocortical Carcinoma/classification , Molecular Mechanisms of Pharmacological Action , Synthetic Lethal Mutations
9.
J Cosmet Laser Ther ; 19(5): 303-306, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28296520

ABSTRACT

Growth factors and cytokines control cell growth, proliferation and differentiation via a network of inter- and intracellular signalling pathways, and are involved in skin self-renewing and wound healing. In recent years, topical and injectable growth factors and cytokines have emerged as an intriguing therapeutic modality that can be harnessed for aesthetic purposes. However, very little data are available on their long-term safety and tolerability. In this report, we describe two cases of patients, who developed intramuscular lipoma of the chin following topical injection with a mixture of basic fibroblast growth factor as the main ingredients for chin augmentation. Biopsies in the two cases were performed at our department, and revealed intramuscular lipoma. Our report indicates that the topical injection of growth factors can lead to tumorigenesis, so health care providers need to be aware of its potential consequences.


Subject(s)
Facial Neoplasms/chemically induced , Fibroblast Growth Factor 2/adverse effects , Lipoma/chemically induced , Muscle Neoplasms/chemically induced , Adult , Chin , Cosmetic Techniques , Female , Humans , Middle Aged
10.
Heart Vessels ; 31(5): 713-21, 2016 May.
Article in English | MEDLINE | ID: mdl-25861983

ABSTRACT

As a form of therapeutic angiogenesis, we sought to investigate the safety and efficacy of a sustained-release system of basic fibroblast growth factor (bFGF) using biodegradable gelatin hydrogel in patients with critical limb ischemia (CLI). We conducted a phase I-IIa study that analyzed 10 CLI patients following a 200-µg intramuscular injection of bFGF-incorporated gelatin hydrogel microspheres into the ischemic limb. Primary endpoints were safety and transcutaneous oxygen pressure (TcO2) at 4 and 24 weeks after treatment. During the follow-up, there was no death or serious procedure-related adverse event. After 24 weeks, TcO2 (28.4 ± 8.4 vs. 46.2 ± 13.0 mmHg for pretreatment vs after 24 weeks, p < 0.01) showed significant improvement. Regarding secondary endpoints, the distance walked in 6 min (255 ± 105 vs. 318 ± 127 m, p = 0.02), the Rutherford classification (4.4 ± 0.5 vs. 3.1 ± 1.4, p = 0.02), the rest pain scale (1.7 ± 1.0 vs. 1.2 ± 1.3, p = 0.03), and the cyanotic scale (2.0 ± 1.1 vs. 0.9 ± 0.9, p < 0.01) also showed improvement. The blood levels of bFGF were within the normal range in all patients. A subanalysis of patients with arteriosclerosis obliterans (n = 7) or thromboangiitis obliterans (Buerger's disease) (n = 3) revealed that TcO2 had significantly improved in both subgroups. TcO2 did not differ between patients with or without chronic kidney disease. The sustained release of bFGF from biodegradable gelatin hydrogel may offer a safe and effective form of angiogenesis for patients with CLI.


Subject(s)
Angiogenesis Inducing Agents/administration & dosage , Drug Carriers , Exercise Tolerance/drug effects , Fibroblast Growth Factor 2/administration & dosage , Gelatin/chemistry , Ischemia/drug therapy , Lower Extremity/blood supply , Neovascularization, Physiologic/drug effects , Peripheral Arterial Disease/drug therapy , Aged , Angiogenesis Inducing Agents/adverse effects , Angiogenesis Inducing Agents/chemistry , Ankle Brachial Index , Blood Gas Monitoring, Transcutaneous , Critical Illness , Delayed-Action Preparations , Drug Compounding , Exercise Test , Female , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/chemistry , Humans , Hydrogels , Injections, Intramuscular , Ischemia/diagnosis , Ischemia/physiopathology , Japan , Male , Microspheres , Middle Aged , Pain Measurement , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/physiopathology , Recovery of Function , Time Factors , Treatment Outcome
11.
Drug Des Devel Ther ; 9: 687-94, 2015.
Article in English | MEDLINE | ID: mdl-25678773

ABSTRACT

PURPOSE: To evaluate the effectiveness and safety of 0.3% sodium hyaluronate (HA) compared to recombinant bovine basic fibroblast growth factor (rb-bFGF) for the treatment of corneal epithelial abrasion caused by mechanical damage in Chinese patients. METHODS: Thirty patients were randomly assigned to the HA or rb-bFGF treatment group. The HA group was treated with 0.3% HA and 0.5% levofloxacin, and the rb-bFGF group was treated with topical rb-bFGF and 0.5% levofloxacin. The primary endpoint was the clinical effectiveness rates at day 3. Secondary endpoints were the dimensions of the wound area and the percentage of wound closure. RESULTS: After 3 days of treatment, the clinical effectiveness rates of the HA group and the rb-bFGF group were 86.67% (13/15) and 93.33% (14/15), respectively. The dimensions of the wound area were reduced from 9.83±8.50 to 0.02±0.06 mm(2) for the HA group at day 7, and from 10.58±9.94 to 0.02±0.07 mm(2) for the rb-bFGF group. At day 3, the wound closure was almost complete in both groups; 94.73% in the HA group compared to 95.77% in the rb-bFGF group (P>0.05). CONCLUSION: Topical 0.3% HA provided a promising treatment for superficial corneal abrasion caused by mechanical damage in a manner similar to rb-bFGF.


Subject(s)
Corneal Injuries/drug therapy , Epithelium, Corneal/drug effects , Fibroblast Growth Factor 2/administration & dosage , Hyaluronic Acid/administration & dosage , Wound Healing/drug effects , Administration, Ophthalmic , Adult , Anti-Bacterial Agents/administration & dosage , China , Corneal Injuries/diagnosis , Epithelium, Corneal/injuries , Epithelium, Corneal/pathology , Female , Fibroblast Growth Factor 2/adverse effects , Humans , Hyaluronic Acid/adverse effects , Levofloxacin/administration & dosage , Male , Middle Aged , Ophthalmic Solutions , Recombinant Proteins/administration & dosage , Time Factors , Treatment Outcome
12.
Health Phys ; 106(6): 704-12, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24776903

ABSTRACT

The effects of fibroblast growth factors and their potential as broad-spectrum agents to treat and mitigate radiation injury have been studied extensively over the past two decades. This report shows that a peptide mimetic of basic fibroblast growth factor (FGF-P) protects and mitigates against acute radiation syndromes. FGF-P attenuates both sepsis and bleeding in a radiation-induced bone marrow syndrome model and reduces the severity of gastrointestinal and cutaneous syndromes; it should also mitigate combined injuries. FGF-2 and FGF-P induce little or no deleterious inflammation or vascular leakage, which distinguishes them from most other growth factors, angiogenic factors, and cytokines. Although recombinant FGFs have proven safe in several ongoing clinical trials, they are expensive to synthesize, can only be produced in limited quantity, and have limited shelf life. FGF-P mimics the advantageous features of FGF-2 without these disadvantages. This paper shows that FGF-P not only has the potential to be a potent yet safe broad-spectrum medical countermeasure that mitigates acute radiotoxicity but also holds promise for thermal burns, ischemic wound healing, tissue engineering, and stem-cell regeneration.


Subject(s)
Acute Radiation Syndrome/prevention & control , Fibroblast Growth Factor 2/analogs & derivatives , Fibroblast Growth Factor 2/pharmacology , Radiation-Protective Agents/chemistry , Radiation-Protective Agents/pharmacology , Acute Radiation Syndrome/blood , Acute Radiation Syndrome/drug therapy , Acute Radiation Syndrome/metabolism , Animals , Blood Coagulation/drug effects , Blood Coagulation/radiation effects , Bone Marrow Cells/cytology , Cell Line , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Cell Survival/drug effects , Cell Survival/radiation effects , Drug Stability , Enzyme Activation/drug effects , Enzyme Activation/radiation effects , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/pharmacokinetics , Lethal Dose 50 , Mice , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphoproteins/metabolism , Platelet Count , Radiation-Protective Agents/adverse effects , Radiation-Protective Agents/pharmacokinetics , Stem Cells/cytology , Stem Cells/drug effects , Stem Cells/radiation effects
13.
Drug Dev Ind Pharm ; 39(11): 1712-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23062067

ABSTRACT

Characterization and antitumor activity of basic fibroblast growth factor-mediated active targeting doxorubicin microbubbles (bFGF-DOX-MB) were investigated. Pluronic F68 with chemical conjugation of doxorubicin (DOX-P) and peptide KRTGQYKLC-conjugated DSPE-PEG2000 were prepared. bFGF-DOX-MB had a normal distribution of particle size, with average particle size of 2.7 µm. Using A549 mouse model, bFGF-DOX-MB combined ultrasound showed the best inhibition effect on tumor volume growth among all the test groups. Similar conclusion was obtained from experimental measurements of tumor weight change and blood cell count. From the results, chemotherapeutic drug inhibition on tumor growth could be enhanced by local ultrasound combined with active targeting bFGF-DOX-MB, which might provide a potential application for ultrasound-mediated chemotherapy.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Doxorubicin/administration & dosage , Drug Delivery Systems , Fibroblast Growth Factor 2/administration & dosage , Lung Neoplasms/drug therapy , Microbubbles/therapeutic use , Oligopeptides/administration & dosage , Peptide Fragments/administration & dosage , Animals , Antibiotics, Antineoplastic/adverse effects , Antibiotics, Antineoplastic/chemistry , Antibiotics, Antineoplastic/therapeutic use , Cell Line, Tumor , Doxorubicin/adverse effects , Doxorubicin/chemistry , Doxorubicin/therapeutic use , Drug Compounding , Drug Delivery Systems/adverse effects , Feasibility Studies , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/chemistry , Fibroblast Growth Factor 2/therapeutic use , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Male , Mice , Mice, Nude , Microbubbles/adverse effects , Neoplasm Proteins/metabolism , Oligopeptides/adverse effects , Oligopeptides/chemistry , Oligopeptides/therapeutic use , Peptide Fragments/adverse effects , Peptide Fragments/chemistry , Peptide Fragments/therapeutic use , Protein Interaction Domains and Motifs , Random Allocation , Receptor, Fibroblast Growth Factor, Type 2/metabolism , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
14.
Otol Neurotol ; 33(9): 1553-7, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23150095

ABSTRACT

OBJECTIVE: The goal of this study was to evaluate the effects of conservative treatment and fibroblast growth factor (FGF) applied directly or via Gelfoam on the healing of large traumatic tympanic membrane perforations (TMPs) in humans. STUDY DESIGN: Prospective, randomized, controlled trial. METHODS: A randomized prospective analysis was performed between February 2009 and January 2011 for the treatment of traumatic TMPs in humans that affected greater than 50% of the TM. The closure rate, closure time, hearing gain, and rate of otorrhea were compared among the direct application of FGF, FGF via Gelfoam, and conservative treatment. RESULTS: A total of 94 patients were analyzed. The closure rates of large perforations in the direct FGF application, FGF via Gelfoam, and observation groups were 100%, 97%, and 55%, respectively. FGF-treated groups had significantly improved closure rates compared with the observation group (p < 0.05). However, the closure rate did not differ significantly between patients who received FGF only and those who received FGF via Gelfoam (p > 0.05). FGF-treated groups showed shorter mean closure times compared with the observation group (p < 0.05). However, the closure time did not differ significantly between FGF-treated groups (p > 0.05).All perforations were closed within 2 weeks, regardless of the presence of curled edges in the FGF-treated groups.


Subject(s)
Fibroblast Growth Factor 2/therapeutic use , Tympanic Membrane Perforation/drug therapy , Administration, Topical , Adolescent , Adult , Aged , Cerebrospinal Fluid Otorrhea/drug therapy , Cerebrospinal Fluid Otorrhea/etiology , Endoscopy , Female , Fibroblast Growth Factor 2/administration & dosage , Fibroblast Growth Factor 2/adverse effects , Follow-Up Studies , Gels , Humans , Male , Middle Aged , Prospective Studies , Sample Size , Treatment Outcome , Tympanic Membrane Perforation/pathology , Young Adult
15.
J Bone Miner Res ; 25(12): 2735-43, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20533373

ABSTRACT

Fibroblast growth factor 2 (FGF-2) is a potent mitogen for mesenchymal cells, and a local application of recombinant human FGF-2 (rhFGF-2) in a gelatin hydrogel has been reported to accelerate bone union in our animal studies and preparatory dose-escalation trial on patients with surgical osteotomy. We have performed a randomized, double-blind, placebo-controlled trial in which patients with fresh tibial shaft fractures of transverse or short oblique type were randomly assigned to three groups receiving a single injection of the gelatin hydrogel containing either placebo or 0.8 mg (low-dosage group) or 2.4 mg (high-dosage group) of rhFGF-2 into the fracture gap at the end of an intramedullary nailing surgery. Of 194 consecutive patients over 2 years, 85 met the eligibility criteria, and 70 (24 in the placebo group and 23 each in low- and high-dosage groups) completed the 24-week study. The cumulative percentages of patients with radiographic bone union were higher in the rhFGF-2-treated groups (p = .031 and .009 in low- and high-dosage group, respectively) compared with the placebo group, although there was no significant difference between low- and high-dosage groups (p = .776). At 24 weeks, 4, 1, and 0 patients in the placebo, low-dosage, and high-dosage groups, respectively, continued to show delayed union. No patient underwent a secondary intervention, and the time to full weight bearing without pain was not significantly different among the three groups (p = .567). There also was no significant difference in the profiles of adverse events among the groups. In conclusion, a local application of the rhFGF-2 hydrogel accelerated healing of tibial shaft fractures with a safety profile.


Subject(s)
Fibroblast Growth Factor 2/administration & dosage , Fibroblast Growth Factor 2/therapeutic use , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Tibial Fractures/drug therapy , Adult , Antibodies/blood , Diabetes Complications/blood , Female , Fibroblast Growth Factor 2/adverse effects , Fibroblast Growth Factor 2/blood , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Placebos , Radiography , Recombinant Proteins/adverse effects , Recombinant Proteins/blood , Tibial Fractures/blood , Tibial Fractures/complications , Tibial Fractures/diagnostic imaging
16.
Eur J Dermatol ; 19(5): 461-8, 2009.
Article in English | MEDLINE | ID: mdl-19638336

ABSTRACT

Basic fibroblast growth factor (bFGF) has been shown to promote wound healing. The present trial evaluated the clinical efficacy of bFGF for diabetic ulcer, a type of refractory skin ulcer, and the dose-response relationship. This was designed as a randomized, double-blind, dose-ranging, placebo-controlled trial. A total of 150 patients with non-ischaemic diabetic ulcers measuring 900 mm2 or less were randomized into a placebo group (n = 51), a 0.001% bFGF group (n = 49) and a 0.01% bFGF group (n = 50), and 148 of these patients received treatment for 8 weeks or less. The efficacy evaluation was carried out on 139 patients who met the protocol in this trial. The primary outcome was the percentage of patients showing 75% or greater reductions in the area of ulcer. The area of ulcer decreased by 75% or more in 57.5% (27/47), 72.3% (34/47), and 82.2% (37/45) in the placebo, 0.001% bFGF and 0.01% bFGF groups, respectively, and differences were significant between the 0.01% bFGF and placebo groups (p = 0.025). The cure rate was 46.8% (22/47), 57.4% (27/47), and 66.7% (30/45) in the placebo, 0.001% bFGF and 0.01% bFGF groups, respectively. The findings obtained in this trial showed wound healing accelerating effects of bFGF on diabetic ulcers.


Subject(s)
Diabetic Foot/drug therapy , Fibroblast Growth Factor 2/therapeutic use , Adult , Aged , Dose-Response Relationship, Drug , Double-Blind Method , Female , Fibroblast Growth Factor 2/adverse effects , Humans , Male , Middle Aged
17.
J Anesth ; 22(4): 449-52, 2008.
Article in English | MEDLINE | ID: mdl-19011787

ABSTRACT

Severe ischemic pain is difficult to treat with a single therapy. Although modern angiogenic therapies have been used in patients with peripheral arterial occlusive diseases, a regimen combining novel angiogenic therapy and classic nerve blocks, including sympathectomy, has not been discussed to date. In this case report, we present two patients with peripheral arterial occlusive disease who were first treated with medication and lumbar sympathectomy, and then with a novel gelatin hydrogel drug-delivery system loaded with basic fibroblast growth factor. The gelatin hydrogel combined with recombinant basic fibroblast growth factor was injected intramuscularly into the ischemic limbs. In the first patient, with arteriosclerosis obliterans, a foot ulcer was healed, and the original score for resting pain (visual analogue scale, 5/10) was decreased to 0/10. In the second patient, with Buerger's disease, a large toe ulcer was healed, and his resting pain (visual analogue scale, 8/10) was decreased to 1/10. Some other parameters, such as skin surface temperature, transcutaneous oxygen partial pressure, and pain-free walking distance, were also improved in both patients after the combined therapy. A multimodal approach is necessary to treat severe ischemic pain. Novel angiogenic therapy combined with nerve blocks seems to be a promising option in patients with severe pain.


Subject(s)
Fibroblast Growth Factor 2/therapeutic use , Growth Hormone/therapeutic use , Ischemia/complications , Pain/drug therapy , Adult , Aged, 80 and over , Arteriosclerosis Obliterans/complications , Arteriosclerosis Obliterans/drug therapy , Extremities/blood supply , Fibroblast Growth Factor 2/administration & dosage , Fibroblast Growth Factor 2/adverse effects , Foot Ulcer/complications , Growth Hormone/administration & dosage , Growth Hormone/adverse effects , Humans , Male , Pain/etiology , Pain Measurement , Pain, Intractable/drug therapy , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Regional Blood Flow , Sympathectomy
18.
Neurosurgery ; 60(5): 926-33; discussion 926-33, 2007 May.
Article in English | MEDLINE | ID: mdl-17460529

ABSTRACT

OBJECTIVE: There is evidence that promoting the proliferation of endogenous neural stem cells in the spinal cord could be an effective strategy in the treatment of spinal cord injury. We studied this proliferation in a minimal injury rat model in the presence of epidermal growth factor and fibroblast growth factor-2. METHODS: Adult female Sprague Dawley rats were minimally injured at T8 and received the growth factors intrathecally by osmotic pump for either 3, 7, or 14 days beginning immediately after spinal cord injury. The infusions were made through a subarachnoid catheter connected to an osmotic minipump. Beginning at the time of injury, the rats received daily bromodeoxyuridine to label proliferating cells for determination of the labeling index. RESULTS: Significant differences were found in the labeling index between injured and non-injured rats. We concluded that minimal spinal cord injury from the stab injury and from the catheter itself increased the proliferation of ependymal region stem/progenitor cells. A minority (23.3%) of the rats developed proliferative lesions in association with the catheters alone, but the lesions were significantly larger and occurred in almost all (93.8%) rats receiving the mitogens, resulting in marked spinal cord compression. CONCLUSION: The large proliferative growths in the epidermal growth factor and fibroblast growth factor-2-treated rats were unexpected and are indicative of the major effects of these mitogens. This suggests that considerable caution is required in devising therapeutic strategies directed toward mitogenic stimulation by growth factors delivered into the subarachnoid space. Further study is required to determine the appropriate and safe dosage of mitogens for potential use in spinal cord repair.


Subject(s)
Catheters, Indwelling , Cell Proliferation/drug effects , Epidermal Growth Factor/administration & dosage , Fibroblast Growth Factor 2/administration & dosage , Meninges/pathology , Animals , Catheters, Indwelling/adverse effects , Epidermal Growth Factor/adverse effects , Female , Fibroblast Growth Factor 2/adverse effects , Humans , Injections, Spinal , Meninges/drug effects , Rats , Rats, Sprague-Dawley
19.
Acta Orthop ; 78(1): 63-73, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17453394

ABSTRACT

INTRODUCTION: Local application of growth factors to stimulate wound and fracture healing is attracting increasing interest. We studied the effect of local application of a potent angiogenic growth factor, basic fibroblast growth factor (bFGF), on resistance to local infection after soft tissue trauma. METHODS: For in-vitro and in-vivo experiments, we used recombinant human bFGF. The in-vitro investigations were performed by isolation of human leukocyte fractions, cytokine analysis, phagocytosis assay, flow cytometry, and LDH assay. For the in-vivo investigation, a paired comparison of infection rates was carried out on Sprague-Dawley rats after standardized, closed soft tissue trauma and local, percutaneous bacterial inoculation of different concentrations of Staphylococcus aureus (2 x 10(4) to 2 x 10(7) colony-forming units (cfu)). The lower leg was treated with 1, 10 or 100 ng bFGF (16 animals for each concentration) and without bFGF (16 animals). RESULTS: Cytotoxic reactions due to the concentrations of bFGF used could be excluded in the in-vitro tests since incubations of isolated peripheral blood mononuclear cells (PBMCs) with increasing concentrations of bFGF for 24 h did not lead to an increase in the release of lactate dehydrogenase in the culture supernatants compared to corresponding control incubations without any bFGF added. A significant increase in cytokine release was observed after the co-incubation of PBMCs with 100 or 200 ng of the same bFGF that was used for the animal experiments. Furthermore, the capacity of phagocytes in whole blood to phagocytose bacteria was suppressed in the presence of 100 ng exogenously added bFGF. We found continuously reduced granulocytic phagocytosis in FGF-supplemented blood compared to non-supplemented blood. In the in-vivo investigation, the infection rate for the group without bFGF was 0.25. In the groups with 1, 10 and 100 ng bFGF, the infection rates were 0.5, 0.7 and 0.8, respectively. A dose-dependent increase in infection rate was observed after local application of bFGF, compared to the untreated control group. The difference in infection rates for the groups in which 10 and 100 ng bFGF was used, relative to the group without bFGF, was statistically significant. INTERPRETATION: If these initial results are confirmed for other potent angiogenic growth factors, then the local use of growth factors for stimulation of wound and bone healing--a main focus of current research in traumatology--will have to be reconsidered and preceded with a strict evaluation of the risks and benefits.


Subject(s)
Bacterial Infections/etiology , Fibroblast Growth Factor 2/administration & dosage , Soft Tissue Injuries/complications , Wound Healing/drug effects , Administration, Topical , Animals , Bacterial Infections/immunology , Bacterial Infections/microbiology , Cytokines/metabolism , Fibroblast Growth Factor 2/adverse effects , Humans , In Vitro Techniques , Leukocytes/immunology , Male , Phagocytosis/drug effects , Rats , Rats, Sprague-Dawley , Risk Factors , Soft Tissue Injuries/immunology , Soft Tissue Injuries/microbiology , Wound Healing/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...